NCT02923947 - Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

September 20, 2018

Study Completion Date

October 28, 2022

Conditions

Solid Tumours

Interventions

DRUG

Osimertinib; AZD9291

80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit

Trial Locations (11)

21079

Research Site, Dijon

28040

Research Site, Madrid

28046

Research Site, Madrid

28050

Research Site, Madrid

33000

Research Site, Bordeaux

41013

Research Site, Seville

44805

Research Site, Saint-Herblain

49055

Research Site, Angers

59020

Research Site, Lille

03080

Research Site, Seoul

05505

Research Site, Seoul